Aldoxorubicin hydrochloride (0.27 to 2.16 μM) inhibits formation of blood vessel and reduces growth of multiple myeloma cell in a pH-dependent fashion[1].

Aldoxorubicin hydrochloride (10.8 mg/kg, i.v.) exhibits significantly smaller tumor volumes and IgG levels on days 28, and is well tolerated with 90% of mice surviving until the termination of the study in the mice bearing the LAGκ-1A tumor[1]. Aldoxorubicin hydrochloride exhibits a good safety profile at doses up to 260 mg/mL doxorubicin equivalents, and is able to induce tumor regressions in breast cancer, small cell lung cancer and sarcoma in phase I study[2]. Aldoxorubicin hydrochloride exhibits superior activity over doxorubicin in a murine renal cell carcinoma model and in breast carcinoma xenograft models[3].